Last reviewed · How we verify

AM REGENT — Portfolio Competitive Intelligence Brief

AM REGENT pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Injectafer FERRIC CARBOXYMALTOSE marketed Hematology 2013-01-01
Zinc Sulfate ZINC SULFATE marketed zinc sulfate Immunology 1987-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for AM REGENT:

Cite this brief

Drug Landscape (2026). AM REGENT — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/am-regent. Accessed 2026-05-14.

Related